Login to Your Account



'Déjà Vu All Over Again'

New PML Cases Mar Tysabri's Two-Year Anniversary in MS

By Jennifer Boggs


Monday, August 4, 2008
Biogen Idec Inc. and Elan Corp. plc reported two new cases of PML — though not much else, to the chagrin of investors and analysts — linked to multiple sclerosis therapy Tysabri (natalizumab), spoiling the controversial drug's two-year anniversary of its re-launch onto the market. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription